Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

导出原文传递

翻译打印收藏纠错

作者： Fischer T ^[1] ; Stone RM ; Deangelo DJ ; Galinsky I ; Estey E ; Lanza C ; Fox E ; Ehninger G ; Feldman EJ ; Schiller GJ ; Klimek VM ; Nimer SD ; Gilliland DG ; Dutreix C ; Huntsman Labed A ; Virkus J ; Giles FJ

作者单位： Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA. ^[1]

发布时间 2013-11-20

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览5

Journal of Clinical Oncology

2010年28卷28期

4339-4345页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Journal of Clinical Oncology

相似文献

Journal of Clinical Oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.

Journal of Clinical Oncology

相似文献

Journal of Clinical Oncology

相关期刊

检索历史清除